Bimatoprost in the treatment of eyelash universalis alopecia areata

Teresa Ojeda Vila, Francisco M Camacho Martinez, Teresa Ojeda Vila, Francisco M Camacho Martinez

Abstract

Objectives: To evaluate topical bimatoprost for eyelash growth in patients with alopecia areata (AA).

Design: A 1-year retrospective study, bilateral eyelash alopecia.

Materials and methods: Forty-one subjects with AA universalis without ocular disease applied 0.03% bimatoprost to the eyelid margin once a day over the course of 1 year.

Results: Thirty-seven subjects completed the study, one patient was eliminated due to conjunctivitis at the beginning of treatment, two patients developed conjunctivitis after 6 months of treatment, and a fourth did not follow directions. Researchers evaluated patients' eyelash growth every 4 months. We observed complete growth in 24.32%, moderate growth in 18.91%, slight growth in 27.02% and without response in 29.72%.

Conclusion: Bimatoprost may be effective and safe in the treatment of eyelash AA. 43.24% of the patients had an acceptable cosmetic response (total and moderate growth).

Limitations: Design without control.

Keywords: Alopecia areata; bimatoprost; eyelash growth; prostaglandins.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Responses to bimatoprost 0.03%
Figure 2
Figure 2
Moderate regrowth after 1 year of using bimatoprost
Figure 3
Figure 3
Moderate regrowth after 8 months of treatment with bimatoprost
Figure 4
Figure 4
Recurrence during the treatment

References

    1. Johnstone MA. Hypertrichosis and increased pigmentation of eyelash and adjacent hair in the región of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544–7.
    1. Woodward JA, Haggerty CJ, Stinnett SS, Williams ZY. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol. 2010;9:96–102.
    1. Sarifakioglu E, Degim IT, Gorpelioglu C. Determination of the sildenafil effect on the alopecia areata in childhood: An open-pilot comparison study. J Dermatolog Treat. 2006;17:235–7.
    1. Coronel-Pérez IM, Rodréguez-Rey EM, Camacho-Marténez FM. Latanoprost in the treatment of eyelashes alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010;24:481–5.
    1. Ochoa BE, Sah D, Wang G, Stamper R, Price VH. Instilled bimatoprost ophthalmic solution inpatients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61:530–2.
    1. Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol. 2004;51:S149–50.
    1. Bikowski J, Lau EG, Jacob SE. Eyelash growth: A beneficial side effect of prostaglandin analogues. Cutis. 2010;85:187–8.
    1. Lim KS, Nau CB, O’Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanopros, and tavoprost in healthy subjects. A crossover study. Ophtalmology. 2008;115:790–5. e4.
    1. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–58.
    1. Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology. 2010;117:1024–31.
    1. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 2009;60:705–6.
    1. Zaheri S, Hughes B. Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol. 2010;35:e161–2.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever